- Push-out Score determined
- After about five years in the position
- Praise, thanks and good wishes for Gould
- Bryan Stuart taking over
(exechange) — Cambridge, Massachusetts, March 4, 2021 — Robert Gould, chief executive of Fulcrum, leaves. As announced by Fulcrum Therapeutics Inc. in a news release on Thursday, March 4, 2021, Robert J. Gould leaves his post as chief executive officer at the clinical-stage biopharmaceutical company after about five years in the role, effective March 31, 2021.
Robert Gould’s duties as CEO will be taken over by Bryan E. Stuart, currently chief operating officer of Fulcrum Therapeutics Inc.
It is a generational change as well. Bryan Stuart is about 22 years younger than Robert Gould.
No reason given
In the announcement, Fulcrum did not explicitly explain the reason for Robert Gould’s move, leaving room for speculation.
Precise information regarding Robert Gould’s future plans was not immediately available.
Fulcrum said: “Mr. Stuart will succeed current president and chief executive officer Robert J. Gould, Ph.D. who will be retiring as of March 31, 2021.”
Share price decline since March 2020
The announcement follows a decline in Fulcrum Therapeutics Inc.’s share price of 19% since March 2020.
Chaired by Mark Levin
Mark Levin serves as Fulcrum Therapeutics Inc.’s Chairman.
Mark Levin has served as a member of the Company’s board of directors since August 2015 and chairman of the Company’s board of directors since August 2016.
In the position of CEO since 2016
Robert Gould became CEO of the Company in 2016.
Gould will remain as a member of the Board of Directors and will serve as an advisor to the company.
Additionally, Mark Levin, Fulcrum’s Board chair, will assume the role of executive chair effective upon Gould’s retirement.
Robert J. Gould, Ph.D., has served as the Company’s president and chief executive officer and as a member of the Company’s board of directors since July 2016.
Gould previously served as president and chief executive officer of Epizyme, Inc., or Epizyme, a biopharmaceutical company, from March 2010 to September 2015.
Prior to joining Epizyme, he served as director of novel therapeutics at the Broad Institute of Massachusetts Institute of Technology, or MIT, and Harvard, a research institute, from December 2006 to March 2010.
Gould spent 23 years at Merck Research Laboratories, or Merck, a healthcare company, where he held a variety of leadership positions, culminating in the role of vice president, licensing and external research.
Gould received a B.A. from Spring Arbor University and a Ph.D. from the University of Iowa and completed postdoctoral studies at the Johns Hopkins University.
Push-out Score determined
The Push-out Score™ determined by exechange gauges the pressure surrounding Robert Gould’s move on a scale of 0 to 10.
exechange reached out to Fulcrum and offered the company the opportunity to comment on the score.
Read the full story in the exechange report 10.2021 ($).